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ABSTRACT 
REVASCAT is a multi-center, randomized, sequential and blinded-endpoint trial. 
Subjects presenting with acute ischemic stroke within 8 hours from symptom onset and 
CT angiography (CT) or MR angiography (MRA) proven arterial occlusion of the 
internal carotid or proximal middle cerebral artery (MCA) (M1) who are either ineligible 
for intravenous IV alteplase or have received IV alteplase therapy without 
recanalization will be randomized following a 1:1 ratio to receive mechanical 
embolectomy with the CE MARK approved stentriever SolitaireTM FR revascularization 
device or medical management alone. The overall goal of the REVASCAT trial is to 
establish whether subjects with a baseline NIHSS ≥ 6 and large artery occlusion of the 
anterior territory who can potentially undergo endovascular treatment within 8 hours 
from the time last seen well have a more favorable outcome at 3 months as compared 
to subjects treated with standard medical therapy aloneThe primary endpoint on the 
basis of intention-to-treat criteria will be the distribution of the modified Rankin Scale 
scores at 90 days. Sample size is projected to be 690 patients for an estimated 
common odds ratio of 1.615. 
Randomization will be done under a minimization process using investigational center, 
age, baseline NIHSS, therapeutic window and vessel occlusion site. The study follows 
a sequential analysis (triangular model), with the first approach to test efficacy in 174 
patients.  If the study is continued at this point, further analyses will take place when 
data are available on 346, 518 and 690.  
Salvageable brain will be evaluated by the Alberta Stroke Program Early CT score 
(ASPECTS) score on non-contrast CT or on diffusion-weighted MRI DWI-MRI. 
Secondary endpoints are infarct volume evaluated on CT at 24 hours, dramatic early 
favorable response as determined by an National Institutes of Health Stroke Scale 
(NIHSS) of 0-2 or NIHSS improvement ≥ 8 points at 24 hours, vessel recanalization 
evaluated by CTA or MRA at 24 hours in both treatment groups and successful 
recanalization in the Solitaire arm according to the Thrombolysis in Cerebral Infarction 
(TICI) classification assessed by TICI (Thrombolysis in Cerebral Infarction) 2b or 3 on 
the post-procedure angiogram adjudicated by a central core-lab. 
Safety variables will be mortality at 90 days, symptomatic intracranial hemorrhage 
(ICH) rates at 24 hours and procedural related complications: arterial perforation, 
arterial dissection, and embolization in a previously uninvolved vascular territory 
adjudicated by an independent committee. 
 
BACKGROUND 
Intravenous thrombolysis remains the only approved therapy for acute ischemic stroke. 
However, it has a short therapeutic window, a strong time-dependency, and has only 
marginal benefit in strokes due to proximal arterial occlusions (1,2). Endovascular 
therapy has many theoretic advantages over iv thrombolysis. Mechanical 
thrombectomy reduces and may even preclude the use of chemical thrombolytics and 
this may further reduce the risk of ICH, allowing faster and sustained recanalization. 
However, endovascular recanalization techniques have also relevant disadvantages, 
including delays in initiating treatment, complexity of the procedure, high level of 
required technical expertise, low availability and risks and expense of an invasive 
procedure as compared with iv tPA.. Nevertheless, given the strong relationship 
between vessel recanalization and good clinical outcomes, the advantages of 
endovascular stroke therapy as the most efficacious treatment for recanalization of 
large vessel intracranial occlusions may outweigh its disadvantages and risks, but this 
needs yet to be proved. 
Novel stent retrievers or “stentrievers”, intracranial stents that are deployed and 
retrieved snaring the thrombus showed very promising results (3,4). Recently, the 
SOLITAIRE™ With the Intention for Thrombectomy (SWIFT) trial compared two 
mechanical thrombectomy devices: The MERCI retriever and the SOLITAIRE 
retrievable stent in the arterial recanalization of patients with acute ischemic stroke (5). 
The SWIFT trial has shown in 113 patients that the Solitaire™ FR device is superior to 
the MERCI® Retriever in achieving successful revascularization (by Corelab, 68% vs 
30%, <0.001), inducing less symptomatic intracranial hemorrhage (2% vs 11%, 
p=0.06), reducing mortality (17% vs 38%, p=0.02), and increasing good neurologic 
outcome 3 months after stroke (58% vs 33%). TREVO® Retrival System has also 
shown a high rate of revascularization and favorable results (6). Results of the recently 
reported TREVO 2 trial (7) confirmed the superiority of stentrievers over Merci 
embolectomy with respect to recanalization rates (TICI≥2 in 86.4 vs 60% respectively, 
p<0.00001), clinical outcomes (mRS≤2 in 40% vs 21.8% respectively, p=0.01) and with 
no significant difference in the risk of SIHC (6.8% vs 8.9% respectively, p=0.78). A 
recently published single-center comparison between Merci and Trevo/Solitaire 
showed similar results, with even significant difference in the SICH rate (TICI 2b-3 82 
vs 62%, p=0.016, mRS≤2 65 vs 35%, p=0.002 and SICH 10 vs 28%, p=0.01) (8). In 
none of the aforementioned trials, multimodal imaging showing tissue at risk was used 
for patient’s selection. 
The IMS-3 was a phase III, randomized, multi-center, open label, 900 subject clinical 
trial conducted to examine whether a combined intravenous (IV) and intra-arterial (IA) 
approach to recanalization was superior to standard IV rt-PA alone when initiated 
within three hours of acute ischemic stroke onset (9). The trial was prematurely halted 
due to futility according to the results of a pre-specified interim analysis. The proportion 
of patients who achieved a mRS scoe  mRS≤2 at 90 days did not differ significantly 
according to treatment (40.8% with endovascular therapy and 38.7% with intravenous 
t-PA; Findings in the endovascular-therapy and intravenous t-PA groups were similar 
for mortality at 90 days (19.1% and 21.6%, respectively; P=0.52) and the proportion of 
patients with symptomatic intracerebral hemorrhage within 30 hours after initiation of t-
PA (6.2% and 5.9%, respectively; P=0.83). 
Of note, different intraarterial approaches and devices were allowed during the trial and 
patients were randomized after the initiation of IV tPA without knowledge of vessel 
status. Therefore, there is equipoise on endovascular therapy for acute stroke so far. 
The ideal thrombectomy trial design should test a single device, randomize patients 
according to intracranial occlusion, include tPA non-responders and use advanced 
imaging for patients selection beyond 4.5 hours. In addition, the trial should be 
conducted in a few centres with high recruitment capacity and neurointerventional 
expertise to decrease intercentre variability.  
Following this approach, the overall goal of the REVASCAT trial is to establish whether 
subjects with a baseline NIHSS ≥ 6 and large artery occlusion of the anterior territory 
who can potentially undergo endovascular treatment within 8 hours from the time last 
seen well have a more favorable outcome at 3 months as compared to subjects treated 
with standard medical therapy alone. 
 
 
METHODS 
Study design and participants 
REVASCAT is a multi-center, randomized, sequential and blinded-endpoint trial. The 
randomization employs a 1:1 ratio of mechanical embolectomy with approved 
stentriever Solitaire FR® versus standard medical management alone. 
Eligibility Criteria 
1. Patients with acute ischemic stroke ineligible for IV thrombolytic treatment (e.g., 
subject presents beyond recommended time from symptom onset), or treated with IV 
thrombolytic therapy without recanalization after a minimum of 30 min from start of iv 
tPA infusion 
2. Occlusion (TICI 0-1) of the intracranial ICA (distal ICA or T occlusions), MCA-M1 
segment or tandem proximal ICA/MCA-M1 suitable for endovascular treatment, as 
evidenced by CTA, MRA or angiogram, with or without concomitant cervical carotid 
occlusion or stenosis. 
3. Patient treatable within 8 hours from time last seen well at baseline (i.e., subjects 
who have stroke symptoms upon awakening will be considered to have their “onset” at 
beginning of sleep)  
4. Age ≥18 and ≤ 80 
5. Baseline NIHSS score must be equal or higher than 6 points 
6. No significant pre-stroke functional disability (mRS ≤ 1) 
7. Informed consent obtained from patient or acceptable patient surrogate 
Exclusion Criteria 
Clinical 
1. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant 
therapy with INR > 3.0 
2. Baseline platelet count < 30.000/μL 
3. Baseline blood glucose of < 50mg/dL or >400mg/dl 
4. Severe, sustained hypertension (SBP > 185 mm Hg or DBP > 110 mm Hg)  
5. Patients in coma (NIHSS item of consciousness >1) (Intubated patients for transfer 
could be randomized only in case an NIHSS is obtained by a neurologist prior 
transportation). 
6. Seizures at stroke onset which would preclude obtaining a baseline NIHSS 
7. Serious, advanced, or terminal illness with anticipated life expectancy of less than 
one year. 
8. History of life threatening allergy (more than rash) to contrast medium 
9. Subjects who have received iv t-PA treatment beyond 4,5 hours from the beginning 
of the symptoms. 
10. Renal insufficiency with creatinine ≥ 3 mg/dl 
11. Woman of childbearing potential who is known to be pregnant or lactating or who 
has a positive pregnancy test on admission. 
12. Subject participating in a study involving an investigational drug or device that 
would impact this study. 
13. Cerebral vasculitis 
14. Patients with a pre-existing neurological or psychiatric disease that would confound 
the neurological or functional evaluations; mRS score at baseline must be ≤ 1.  
15. Unlikely to be available for 90-day follow-up  
Neuroimaging 
16. Hypodensity on CT or restricted diffusion amounting to an ASPECTS score of <7 
on non-contrast CT, or <6 on DWI MRI. ASPECTS may be also evaluated by cerebral 
blood flow (CBV) maps of CT Perfusion, or CTA source imaging (CTA-SI) in patients 
whose vascular occlusion study (CTA/MRA) confirming qualifying occlusion, is 
performed beyond 4.5 hours of last seen well. 
17. CT or MR evidence of hemorrhage (the presence of microbleeds is allowed). 
18. Significant mass effect with midline shift. 
19. Evidence of ipsilateral carotid occlusion, high grade stenosis or arterial dissection in 
the extracranial or petrous segment of the internal carotid artery that cannot be treated 
or will prevent access to the intracranial clot or excessive tortuosity of cervical vessels 
precluding device delivery/deployment 
20. Subjects with occlusions in multiple vascular territories (e.g., bilateral anterior 
circulation, or anterior/posterior circulation) 
21. Evidence of intracranial tumor (except small meningioma). 
 
Randomization 
A “Real-Time” randomization procedure is implemented via the REVASCAT Trial 
Website. First, the clinical center investigator enters the basic baseline and eligibility 
information of a subject. If the subject’s eligibility status is confirmed, the server 
allocates the treatment on the basis of a minimization process to balance in a 1:1 ratio 
the 2 groups both overall as well as within every category of the factors: 
investigational center, age (≤70 or >70 years), baseline NIHSS (6-16 or, ≥17-or more), 
therapeutic window (≤4.5 or >4.5 hours), and occlusion site (intracranial ICA or M1 
segment).  
 
Treatment 
Vascular neurologists and trained interventional neuroradiologists or neurologists in 
certified comprehensive stroke centres that treat more than 500 acute stroke patients 
and perform more than 60 acute mechanical thrombectomies every year will treat 
patients. Neurointerventionalists must have previously performed at least 20 
thrombectomies with Solitaire device in acute ischemic stroke patients. Patients in both 
arms will be admitted at acute stroke units (or ICU if needed) and treated following the 
European Stroke Organization ESO guidelines (ESO Cerebrovasc Dis 2008).  
 
All interventional therapy must be started earlier than eight hours relative to the time 
the subject was last seen well. Treatment initiation is defined as groin puncture. The 
duration of the interventional procedure should not exceed three hours. To allow an 
intention to treat interpretation, no crossover is permitted. 
 Endovascular therapy in the REVASCAT will adhere strictly to the following treatment 
principles: 
1. Only the Solitaire FR device will be allowed in REVASCAT. 
2. If the Solitaire device fails after a maximum of six passes per vessel, no 
pharmacological or other mechanical rescue therapies will be allowed. 
3. Systemic anticoagulation may not be used other than in the heparinized saline 
infusion as per local interventional procedure standards. 
4. Balloon angioplasty and/or stenting of extracranial ICA in cases with ICA/M1 tandem 
occlusions will be allowed as per site specific protocols. For sites that perform stenting 
in addition to angioplasty for tandem occlusions, it is recommended that aspirin 300 mg 
and clopidogrel load (600 mg) are administered orally or via nasogastric tube prior to 
intervention if possible 
5. Angioplasty and/or stenting of intracranial vessels beyond the petrous segment of 
the ICA will not be allowed. 
6. The use of a balloon guide catheter in the proximal ICA is highly recommended but  
optional and solely at the discretion of the interventionalist. The rationale for using the 
ballon guide catheter is to prevent distal embolization including in previously uninvolved 
territories during device and clot retrieval.  
 
Efficacy endpoints 
Primary endpoint 
The primary endpoint will be the distribution of the modified Rankin Scale scores at 90 
days (shift analysis) as evaluated following a structured interview by two separate 
certified assessors who will be blinded to treatment.  
 
Clinical secondary endpoints 
1. Early response to treatment as determined by a NIHSS drop of ≥8 or NIHSS 0-2 at 
24 (-2/12) hours from randomization or before discharge if patient is discharged prior to 
the above time limit  
2. Barthel Index at 90 days 
3. NIHSS at 90 days 
4. mRS score (0-2 versus 3-6) at 12 months 
5. Trail Making Test at 90 days 
6. Quality of life measured by EuroQol EQ-5D at 90 days and 12 months 
7. Cost effectiveness analysis 
8. Secondary analyses of the primary endpoint: Functional independence defined as 
mRS ≤ 2 at 90 days and severe dependence defined as mRS > 3 at 90 days 
Neuroimaging secondary endpoints 
1. Final infarct volume measured on 24 (-2/12) hours CT (MRI’s if available will be used 
in a separate analysis).  
2. Median modified ASPECTS score increase defined as CT ASPECTS score at 24 
hours minus baseline ASPECTS score. 
3. Vessel recanalization evaluated by CT angiography or MRA at 24 (-2/12) hours in 
both treatment groups  
4. Immediate Post-Endovascular Treatment Recanalization (for the mechanical 
embolectomy group group only). Successful recanalization is defined as TICI 
(Thrombolysis in Cerebral Infarction) 2b or 3 in the post-procedure angiography. 
 
 
Safety end-points 
1. Clinically significant ICH rates at 24 (-2/+12) hours. All intracerebral hemorrhages 
will be classified by a central core-lab using the ECASS criteria. Symptomatic ICH will 
be defined as per the Safe Implementation of Thrombolysis in Stroke-Monitoring 
Study (SITS-MOST) definition: deterioration in NIHSS score of ≥4 points within 24 
hours from treatment and evidence of intraparenchymal hemorrhage type 2 in the 22 to 
36 hours follow-up imaging scans. The incidence of any asymptomatic hemorrhage 
measured at 24 (-2/+12) hours will also be compared at day 90 
2. Mortality at day 90. 
3. Procedural related complications: arterial perforation, arterial dissection, imposibility 
to retrieve the stent, and embolization in previously uninvolved vascular territory 
 
Masking 
Each site will designate one or more individual(s) to perform the follow-up evaluation at 
24 (±12) hours, 5 (±2) days or prior to discharge if discharge occurs before 3 days and 
at 3 months who can remain blinded to the treatment of each subject. Data entry would 
not reveal the study arm assignment and patients will be instructed to minimize the 
chance of disclosing their treatment group to the evaluator. 
Regarding the primary endpoint, first, a local independent neurologist, not involved in 
the trial patient management, will record the mRS score in a face to face clinical visit; 
and second, an experienced nurse will centrally evaluate mRS score by telephone call, 
recording the interview in an audio-tape. In case of disagreement between the two 
assessors, a centralized neurologist will rate mRS by using the audio-tape recording 
and his mark will be the primary endpoint value in this case. All of them will directly 
introduce mRS score in the database without access to any further information. 
All neuroimaging secondary endpoints including recanalization at 24 hours, infarct 
volume and hemorrhage will be determined by the CT/MR core lab which will be also 
blinded to treatment allocation. Successful recanalization in the post-procedure 
angiography in the mechanical embolectomy group will be classified by a specific  
core-lab. 
Serious adverse events (SAEs) will be adjudicated by one member of the independent 
Clinical Events Committee that will be blinded to treatment arm, and procedural related 
complications will be adjudicated by one member that will be unmasked.  
 
Data safety monitoring board (DSMB) 
 The purpose of the DSMB is to review, on a regular basis, unmasked accumulated 
efficacy and safety data. The DSMB will be composed of three stroke neurologists or 
interventionalists, and a statistician who are not participating in the study and are not 
affiliated with the sponsor. Members of the DSMB are listed in the appendix. The role 
of the DSMB will be to: 1) make recommendations to the Executive Committee 
regarding stopping or extending the trial based on the pre-planned efficacy interim 
analysis; and 2) review the occurrence of AEs and make recommendations to the 
Executive Committee regarding safety of the study. 
 
Imaging Core Lab 
Centralized imaging core labs will be used in this study to provide consistent evaluation 
of images. Two independent central imaging core labs will be established to 
independently review CT/MR and angiographic images. One lab will review 
angiographic images from the procedure to determine clot location and 
revascularization. Another independent core lab will review CT/MR images obtained at 
baseline and at 24 hours for confirmation of inclusion criteria (occlusion of the 
intracranial ICA and/or MCA-M1 with or without concomitant cervical carotid occlusion 
or stenosis; ASPECTS score), and presence/absence of hemorrhage, vessel patency 
and infarct volume at 24 (-2/+12) hours. Having a CT/MR core lab independent from 
the angiographic core lab ensures that the CT/MR core lab is blinded to the treatment. 
Each core lab will use standardized procedures for neuroimaging evaluation defined in 
a specific manual. They will provide no information to the investigators with the 
exception of the deviations from the neuroimaging inclusion criteria. 
 
Clinical Events Committee (CEC) 
A CEC will be in place for the study using a minimum of 2 physicians knowledgeable in 
the appropriate disciplines and medical specialties pertinent to the disease state being 
evaluated in this clinical study. The CEC will be comprised of individuals who are 
independent of the investigational sites. This committee will be responsible for the 
review and validation of all complications that occur over the course of the study and 
the subsequent classification of these complications as related to the device or 
procedure. 
Members of the CEC will review all complications and adjudicate them as defined in 
the Adverse Event section in the CEC Manual of Operations. The CEC can request 
additional source documentation and any imaging obtained in support of the adverse 
event to assist with adjudication. 
 
Statistical design 
Effect size measure and primary endpoint analysis.  
We expect that the effect of the revascularization will improve patient status for the first 
5 mRS possible cut-points, but not for the change between 5 and 6. In other words, the 
intervention may “shift” patients to minor values from 5 to 4; from 4 to 3, from 3 to 2; 
from 2 to 1 and from 1 to 0, but not from 6 to 5. Furthermore, the order preference 
between those two values, severe disability and death, is not clear neither for patients, 
clinicians, nor care providers (10). The Ordinal Logistic Analysis (OLR) based on 
cumulative logits provides a treatment effect in the form of a common estimate of the 
OR for improvement over considered cut-points. This analysis has been shown to be 
robust for minor deviations of the assumption of a common OR underlying behind any 
cut-point (11). This logistic regression will adjust both for the minimization factors and 
for the interventionist. 
Interim analyses rationale  
We desired a maximum of 4 looks when approximately 25, 50, 75 and 100% of the 
sample sizes finish the follow-up, monitoring and data cleaning processes. A sequential 
test strategy was designed to have reasonable chances of stopping as soon as 
possible, either because of better efficacy of the device procedure or because of the 
futility of the trial. We were not interested in proving that the test intervention was 
inferior to the best medical treatment.  
At interim analysis, in case the stopping boundaries are crossed, the DSMB may 
recommend stopping the study either for efficacy or for futility. When addressing safety, 
DSMB will also consider mortality (mRS=6) and severe dependency (mRS=5) at 3 
months as one single value.  In case of early stopping, any over-running patient will be 
followed until the end of the study and a final analysis will be performed. 
Devised effect, power and sample size.  
The expected proportions of patients having a mRS score 0 or 1 at 90 days are 25% 
and 35% in the control and treated arms. This results in an expected OR of 1.615. The 
trial was designed to have 90% chances to conclude efficacy in the case of a clinical 
advantage of a common OR of 1.615 through any possible mRS cut-points (including 5 
to 6) and an overall 2.5% one-sided risk of concluding efficacy in case of no effect. 
After a search (12) a triangular test with 3 interim looks plus 1 final analysis was 
specified with values a = 2.18074 and v1 = 14.008681. The total maximum sample size 
was 690.  
The trials proprieties for the final analysis, pooling mRS values 5 and 6, were validated 
by simulation including two higher hypothetical OR: 2.00 (15%: 40 over 25% on the 0 
or 1 versus 2 to 6 cut-point) and 2.45 (20%: 45 over 25%). Three hypothetical different 
scenarios (figures 1 to 3) for the treatment effect were analysed: (A) the targeted 
studied effects (1,615; 2.000 and 2.450) applies exactly to the 6 frontiers or cut-point 
on the 0 to 6 ranking scale; (B) as before, but the targeted effects are constant for the 5 
first frontiers and they are diluted in the last 5 to 6 cut-point resulting in a diluted overall 
estimate (common along the 6 overall possible frontiers); and (C) as before, but now 
the diluted overall estimate fits the targeted effects.  
 
 
Figure 1: In scenario A, the same OR (either 1.62; 2.00 and 2.45) applies to any possible 
cut-point. 
 
 Figure 2: In scenario B, the same OR (1.62; 2.00 and 2.45) applies only to the first 5 cut-
points, and it is diluted in the last 5 to 6 frontier. As a consequence, the common 
(“averaged”) OR estimated through all cut-points, including the 5 to 6 frontier is smaller. 
 
Figure 3: In scenario C, again, the same OR applies to the first 5 cut-points and it is diluted 
in the last 5 to 6 frontier; but now the common averaged OR results in an estimate of 1.62; 
2.00 and 2.45. 
On those three scenarios, two analysis strategies were compared: considering the full 
mRS scale with the 6 possible cut-points versus just 5 (after pooling values 5 and 6). 
As it was expected, both analyses performed better on the scenarios were their 
assumptions better hold: the first analysis on scenario A (with almost negligible 
differences), and the second on B and C (with more relevant advantages). As 
scenarios B and C are both more realistic and more desired for patients and care 
providers, the analysis pooling values 5 and 6 was chosen as the final analysis. Its 
power on the 3 considered scenarios (87.7%, 88.8% and 93.7%) was considered 
reasonable by the steering committee.  
267
N n Futility Positive Both Futility Positive Both Futility Positive Both Futility Positive Both
174 87 29.1% 0.5% 29.6% 1.2% 18.0% 19.2% 0.0% 42.4% 42.4% 0.0% 70.0% 70.0%
346 173 49.6% 0.9% 50.5% 3.2% 41.6% 44.8% 0.3% 47.7% 48.0% 0.0% 29.5% 29.5%
518 259 16.0% 0.7% 16.7% 4.7% 20.4% 25.1% 0.1% 8.6% 8.7% 0.0% 0.5% 0.5%
690 345 2.9% 0.3% 3.2% 2.2% 8.7% 10.9% 0.0% 0.9% 0.9% 0.0% 0.0% 0.0%
97.6% 2.4% 100% 11.3% 88.7% 100% 0.4% 99.6% 100% 0.0% 100% 100%
Prob(N>518) 2.9% 0.3% 3.2% 2.2% 8.7% 10.9% 0.0% 0.9% 0.9% 0.0% 0.0% 0.0%
267
N n Futility Positive Both Futility Positive Both Futility Positive Both Futility Positive Both
174 87 29.7% 0.3% 30.0% 1.2% 17.6% 18.8% 0.0% 42.4% 42.4% 0.0% 69.8% 69.8%
346 173 49.6% 0.6% 50.2% 3.9% 40.1% 44.0% 0.4% 46.7% 47.1% 0.0% 29.6% 29.6%
518 259 15.2% 1.0% 16.2% 5.2% 22.0% 27.2% 0.1% 9.4% 9.5% 0.0% 0.6% 0.6%
690 345 3.1% 0.5% 3.6% 2.0% 8.0% 10.0% 0.0% 1.0% 1.0% 0.0% 0.0% 0.0%
97.6% 2.4% 100% 12.3% 87.7% 100% 0.5% 99.5% 100% 0.0% 100% 100%
Prob(N>518) 3.1% 0.5% 3.6% 2.0% 8.0% 10.0% 0.0% 1.0% 1.0% 0.0% 0.0% 0.0%
267
N n Futility Positive Both Futility Positive Both Futility Positive Both Futility Positive Both
174 87 0.6% -0.2% 0.4% 0.0% -0.4% -0.4% 0.0% 0.0% 0.0% 0.0% -0.2% -0.2%
346 173 0.0% -0.3% -0.3% 0.7% -1.5% -0.8% 0.1% -1.0% -0.9% 0.0% 0.1% 0.1%
518 259 -0.8% 0.3% -0.5% 0.5% 1.6% 2.1% 0.0% 0.8% 0.8% 0.0% 0.1% 0.1%
690 345 0.2% 0.2% 0.4% -0.2% -0.7% -0.9% 0.0% 0.1% 0.1% 0.0% 0.0% 0.0%
H0: OR=1 H1: OR=1.62 H0: OR=2 H1: OR=2.45
Expected Ssize 335 395 293 227
Discrepancies
H0: OR=1 H1: OR=1.62 H1: OR=2 H1: OR =2.45
Fixed sample size - 564 270 162
Expected Ssize 335 394 291 226
OLR grouping categories 5 and 6 (1000 simulations) 
OLR without grouping categories 5 and 6 (1000 simulations) 
H0: OR=1 (∆ = 0) H1: OR=1.62 (∆ = 0.10) H1: OR=2 (Δ=0.15) H1: OR =2.45 (Δ=0.2)
Fixed sample size - 564 270 162
 
Table 1: Results for both analyses in scenario A, as well as their difference. 
267
N n Futility Positive Both Futility Positive Both Futility Positive Both Futility Positive Both
174 87 29.1% 0.5% 29.6% 1.7% 13.6% 15.3% 0.0% 37.8% 37.8% 0.0% 67.5% 67.5%
346 173 49.6% 0.9% 50.5% 4.4% 37.2% 41.6% 0.1% 49.4% 49.5% 0.0% 30.9% 30.9%
518 259 16.0% 0.7% 16.7% 5.0% 24.2% 29.2% 0.3% 11.2% 11.5% 0.0% 1.6% 1.6%
690 345 2.9% 0.3% 3.2% 4.0% 9.9% 13.9% 0.1% 1.1% 1.2% 0.0% 0.0% 0.0%
97.6% 2.4% 100% 15.1% 84.9% 100% 0.5% 99.5% 100% 0.0% 100% 100%
Prob(N>518) 2.9% 0.3% 3.2% 4.0% 9.9% 13.9% 0.1% 1.1% 1.2% 0.0% 0.0% 0.0%
267
N n Futility Positive Both Futility Positive Both Futility Positive Both Futility Positive Both
174 87 29.7% 0.3% 30.0% 1.3% 16.6% 17.9% 0.0% 41.2% 41.2% 0.0% 70.6% 70.6%
346 173 49.6% 0.6% 50.2% 3.5% 41.0% 44.5% 0.0% 48.1% 48.1% 0.0% 28.2% 28.2%
518 259 15.2% 1.0% 16.2% 3.2% 24.4% 27.6% 0.3% 9.6% 9.9% 0.0% 1.2% 1.2%
690 345 3.1% 0.5% 3.6% 3.2% 6.8% 10.0% 0.1% 0.7% 0.8% 0.0% 0.0% 0.0%
97.6% 2.4% 100% 11.2% 88.8% 100% 0.4% 99.6% 100% 0.0% 100% 100%
Prob(N>518) 3.1% 0.5% 3.6% 3.2% 6.8% 10.0% 0.1% 0.7% 0.8% 0.0% 0.0% 0.0%
267
N n Futility Positive Both Futility Positive Both Futility Positive Both Futility Positive Both
174 87 0.6% -0.2% 0.4% -0.4% 3.0% 2.6% 0.0% 3.4% 3.4% 0.0% 3.1% 3.1%
346 173 0.0% -0.3% -0.3% -0.9% 3.8% 2.9% -0.1% -1.3% -1.4% 0.0% -2.7% -2.7%
518 259 -0.8% 0.3% -0.5% -1.8% 0.2% -1.6% 0.0% -1.6% -1.6% 0.0% -0.4% -0.4%
690 345 0.2% 0.2% 0.4% -0.8% -3.1% -3.9% 0.0% -0.4% -0.4% 0.0% 0.0% 0.0%
Discrepancies
H0: OR=1 H1: OR=1.62 H0: OR=2 H1: OR=2.45
Fixed sample size - 564 270 162
Expected Ssize 335 397 295 227
OLR without grouping categories 5 and 6 (1000 simulations) 
H0: OR=1 (∆ = 0)
OLR grouping categories 5 and 6 (1000 simulations) 
H0: OR=1 H1: OR=1.62 H1: OR=2 H1: OR =2.45
Fixed sample size - 564 270 162
Expected Ssize 335 418 305 233
 
Table 2: Results for both analyses in scenario B, as well as their differences. 
 
267
N n Futility Positive Both Futility Positive Both Futility Positive Both Futility Positive Both
174 87 29.1% 0.5% 29.6% 0.7% 19.2% 19.9% 0.1% 46.2% 46.3% 0.0% 75.3% 75.3%
346 173 49.6% 0.9% 50.5% 2.9% 44.6% 47.5% 0.2% 45.5% 45.7% 0.0% 24.3% 24.3%
518 259 16.0% 0.7% 16.7% 3.1% 21.4% 24.5% 0.0% 7.6% 7.6% 0.0% 0.4% 0.4%
690 345 2.9% 0.3% 3.2% 2.2% 5.9% 8.1% 0.0% 0.4% 0.4% 0.0% 0.0% 0.0%
97.6% 2.4% 100% 8.9% 91.1% 100% 0.3% 99.7% 100% 0.0% 100% 100%
Prob(N>518) 2.9% 0.3% 3.2% 2.2% 5.9% 8.1% 0.0% 0.4% 0.4% 0.0% 0.0% 0.0%
267
N n Futility Positive Both Futility Positive Both Futility Positive Both Futility Positive Both
174 87 29.7% 0.3% 30.0% 0.4% 22.6% 23.0% 0.0% 50.2% 50.2% 0.0% 78.5% 78.5%
346 173 49.6% 0.6% 50.2% 2.1% 46.7% 48.8% 0.1% 43.1% 43.2% 0.0% 21.2% 21.2%
518 259 15.2% 1.0% 16.2% 2.3% 19.6% 21.9% 0.0% 6.3% 6.3% 0.0% 0.3% 0.3%
690 345 3.1% 0.5% 3.6% 1.5% 4.8% 6.3% 0.0% 0.3% 0.3% 0.0% 0.0% 0.0%
97.6% 2.4% 100% 6.3% 93.7% 100% 0.1% 99.9% 100% 0.0% 100% 100%
Prob(N>518) 3.1% 0.5% 3.6% 1.5% 4.8% 6.3% 0.0% 0.3% 0.3% 0.0% 0.0% 0.0%
267
N n Futility Positive Both Futility Positive Both Futility Positive Both Futility Positive Both
174 87 0.6% -0.2% 0.4% -0.3% 3.4% 3.1% -0.1% 4.0% 3.9% 0.0% 3.2% 3.2%
346 173 0.0% -0.3% -0.3% -0.8% 2.1% 1.3% -0.1% -2.4% -2.5% 0.0% -3.1% -3.1%
518 259 -0.8% 0.3% -0.5% -0.8% -1.8% -2.6% 0.0% -1.3% -1.3% 0.0% -0.1% -0.1%
690 345 0.2% 0.2% 0.4% -0.7% -1.1% -1.8% 0.0% -0.1% -0.1% 0.0% 0.0% 0.0%
H0: OR=1 H1: OR=1.62 H0: OR=2 H1: OR=2.45
Expected Ssize 335 366 272 211
Discrepancies
H0: OR=1 H1: OR=1.62 H1: OR=2 H1: OR =2.45
Fixed sample size - 564 270 162
Expected Ssize 335 382 281 217
OLR grouping categories 5 and 6 (1000 simulations) 
Fixed sample size - 564 270 162
H0: OR=1 H1: OR=1.62 H1: OR=2 H1: OR =2.45
OLR without grouping categories 5 and 6 (1000 simulations) 
 
Table 3: Results for both analyses in scenario C, as well as their differences.  
 
In case of missing scale value and successful contact with patients or relatives, last 
observation scale value will be carried forward.  Worst scale values will be assigned to 
any documented death or non-successful contact.  
 
Secondary efficacy analyses.  
To check the consistency of the results under hypothetical unmasking of the local 
assessor of mRS, the primary analysis will be repeated for the central mRS evaluator. 
As less reliability is expected for a single ratter, concordance will be based on point and 
interval estimates and non in significant p values. 
The common cumulative OR assumption of the modified Rankin scale will be visually 
evaluated and estimates for any possible cut-point will be also provided. Comparison of 
the primary and secondary outcome endpoints between the trial control group and 
patients treated with endovascular reperfusion therapies outside the REVASCAT trial 
will provide information of external validity. The prospective population-based SONIIA 
database of all cases treated in Catalunya with reperfusion therapies allows performing 
this analysis. The consistency of the results under alternative missing value 
assumptions will also be studied (13).  
A fully specified statistical analysis plan will be approved by the steering committee 
before first interim. 
 
Analysis of Safety Endpoints 
Mortality at 90 days will be assessed for all enrolled subjects. A Kaplan-Meier analysis 
will be done and the mortality rate in each arm at 90 days with accompanying 95% 
confidence intervals will be reported. Every attempt will be made to determine the 
status of each subject who withdraws from the study so that the withdrawal data can be 
used as a censoring point. 
There is currently no standard for defining clinically significant or symptomatic ICH that 
is universally accepted. Thus, in addition to the definition above, it is anticipated that in 
the final analysis, other alternative definitions for symptomatic ICH may also be used 
and analyzed separately for comparison with other studies and historical literature 
(e.g., NINDS, ECASS III, MultiMERCI). The CEC will be tasked with defining the 
criteria to be used in the primary analysis of symptomatic ICH. 
A descriptive analysis of study-defined adverse events will be presented in aggregate 
and by event. The rates and 95% exact Clopper-Pearson confidence intervals will be 
provided. 
 
SOURCE OF FUNDING 
The trial is sponsored by the non-profit foundation “Fundacio Privada Ictus Malaltia 
Vascular”, beneficiary of an unrestricted grant by eV3-Covidien 
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